Chemistry:Ifupinostat
From HandWiki
Ifupinostat (trade name Betlin) is a drug used for the treatment of cancer. It is approved in China for adults with relapsed or refractory diffuse large B-cell lymphoma who have received at least two lines of systemic therapy.[1] It is being developed by BeBetter Med.[2]
Ifupinostat acts as both a phosphoinositide 3-kinase α (PI3Kα) inhibitor and a histone deacetylase (HDAC) inhibitor.[1][3][4]
References
- ↑ 1.0 1.1 "Ifupinostat: First Approval". Drugs 85 (12): 1629–1633. December 2025. doi:10.1007/s40265-025-02248-z. PMID 41028651.
- ↑ "Ifupinostat - BeBetter Med". AdisInsight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800073071.
- ↑ "Dual PI3K/HDAC Inhibitor BEBT-908 Exhibits Potent Efficacy as Monotherapy for Primary Central Nervous System Lymphoma". Targeted Oncology 18 (6): 941–952. November 2023. doi:10.1007/s11523-023-01006-z. PMID 37855991.
- ↑ "Design, synthesis, and biological evaluation of novel triazine-based dual HDAC/PI3K inhibitors for breast cancer therapy". ChemRxiv. 2025. doi:10.26434/chemrxiv-2025-tzwbz.
 |  |
